Inclusion Body Myositis Treatment Market: By Molecule Type, By Distribution Channel, and Geography and forecast to 2030.

Inclusion Body Myositis Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Molecule Type (ACE-083, Aceneuramic Acid ER, ALZ-1903, UX-001P, UX-007, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and forecast to 2030.

Inclusion Body Myositis Treatment Market was valued at US$ 6,224.1 million in 2023 and is expected to grow at an 5.2% CAGR from 2024 to 2030. Inclusion Body Myositis (inclusion body myositis) is a rare and serious muscle disease. It causes inflammation and damage to the muscles, which can lead to weakness and difficulty walking, climbing stairs, or using your hands. inclusion body myositis most often affects people aged 50 years or older. They are more common in men than women. The market is driven by factors such as the increasing incidence of Inclusion Body Myositis due to growing awareness about the disease and its symptoms. Moreover, there is a significant amount of growing population of aging individuals, who are more susceptible to inclusion body myositis. Thus, the rising prevalence of autoimmune diseases that predispose individuals to inclusion body myositis development is likely to result in better treatment options for the disease in the future, driving the growth of the inclusion body myositis treatment market. Additionally, the development of biomarker assays and genetic testing holds promise for personalized treatment approaches. Increasing awareness among healthcare professionals serves as a pivotal driver for the growth of the inclusion body myositis Treatment market. Continuous medical education programs and collaborative efforts among healthcare organizations play a crucial role in disseminating knowledge about inclusion body myositis, empowering healthcare professionals to deliver optimal care and support to affected individuals.

However, the capital-intensive nature of developing treatments and therapies acts as an entry barrier, deterring potential market entrants. In addition to advancements in disease understanding, regulatory incentives for orphan drug development have played a pivotal role in driving growth opportunities in the global inclusion body myositis Treatment market. Governments and regulatory agencies worldwide have implemented policies and incentives to incentivize the development of therapies for rare diseases like inclusion body myositis. These incentives include expedited review processes, extended market exclusivity periods, and financial incentives such as tax credits and grants. Such regulatory support has attracted pharmaceutical companies to invest in orphan drug development and treatment for inclusion body myositis, leading to a surge in the number of therapeutic candidates in various stages of clinical development. The latest trend in the global Inclusion Body Myositis Treatment market is a significant shift towards collaborative efforts between academia and industry for drug development.

Key Developments: 

  • In January 2021, Abcuro announced that it had raised $42 million in a Sanofi Ventures-led series A to advance anti-KLRG1 treatments for autoimmune diseases and cancers. The funding was intended to be used to conduct a proof-of-mechanism clinical trial in patients with sporadic inclusion body myositis (inclusion body myositis)

 

Inclusion Body Myositis Treatment Market Summary

Study Period

2024– 2030

Base Year

2023

CAGR

5.2%

Largest Market

North America

Fastest Growing Market

Asia pacific

Inclusion Body Myositis Treatment Market Dynamics

The rising incidence of the illness, improvements in diagnostic methods, and the creation of cutting-edge treatment approaches targeted at symptom management and disease progression slowing are driving the market for inclusion body myositis. Pharmaceutical companies that conduct research and development for treatments that address the underlying processes of disease, such as immune regulation and protein aggregation, are significant players in the inclusion body myositis market. The development of novel treatments, including gene therapies and biologics, that have the potential to improve outcomes for people with inclusion body myositis is largely dependent on biotechnology companies. Technological developments are significantly enhancing patient management and treatment of the disease. Furthermore, the analysis of patient data using artificial intelligence is being investigated to forecast the course of disease and enhance treatment approaches. Recognizing the complexity of inclusion body myositis and the challenges associated with developing effective treatments, there has been a notable increase in collaborative research initiatives between academic institutions, research organizations, and pharmaceutical companies.

Inclusion Body Myositis Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024– 2030

Market Size in 2023

US$ 6,224.1 million

Market CAGR

5.2%

By Molecule Type

  • ACE-083
  • Aceneuramic Acid ER
  • ALZ-1903
  • UX-001P
  • UX-007
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory frameworks, and reimbursement scenarios.

Download Free Sample Report

Frequently Asked Questions

Inclusion Body Myositis Treatment Market was valued at US$ 6,224.1 million in 2023 and is expected to grow at an 5.2% CAGR from 2024 to 2030.

Acceleron Pharma Inc., Abcuro, Gradalis, Inc., KPI Therapeutics Inc., Milo Biotechnology LLC, and Novartis AG are some of the major players operating in the inclusion body myositis treatment market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period.

North America accounts for the largest market share and is expected to be the primary market driver in the inclusion body myositis treatment market.

High initial investments and costs are expected to limit the growth of the inclusion body myositis treatment market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Inclusion Body Myositis Treatment Market Introduction 
2.1.Global Inclusion Body Myositis Treatment Market  - Taxonomy
2.2.Global Inclusion Body Myositis Treatment Market  - Definitions
2.2.1.Molecule Type
2.2.2.Distribution Channel
2.2.3.Region
3. Global Inclusion Body Myositis Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Inclusion Body Myositis Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Inclusion Body Myositis Treatment Market  By Molecule Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. ACE-083
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Aceneuramic Acid ER
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. ALZ-1903
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. UX-001P
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. UX-007
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Others
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6. Global Inclusion Body Myositis Treatment Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Online Pharmacies
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7. Global Inclusion Body Myositis Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8. North America Inclusion Body Myositis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Molecule Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.ACE-083
8.1.2.Aceneuramic Acid ER
8.1.3.ALZ-1903
8.1.4.UX-001P
8.1.5.UX-007
8.1.6.Others
8.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Hospital Pharmacies
8.2.2.Retail Pharmacies
8.2.3.Online Pharmacies
8.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9. Europe Inclusion Body Myositis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Molecule Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.ACE-083
9.1.2.Aceneuramic Acid ER
9.1.3.ALZ-1903
9.1.4.UX-001P
9.1.5.UX-007
9.1.6.Others
9.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hospital Pharmacies
9.2.2.Retail Pharmacies
9.2.3.Online Pharmacies
9.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10. Asia Pacific (APAC) Inclusion Body Myositis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Molecule Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.ACE-083
10.1.2.Aceneuramic Acid ER
10.1.3.ALZ-1903
10.1.4.UX-001P
10.1.5.UX-007
10.1.6.Others
10.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hospital Pharmacies
10.2.2.Retail Pharmacies
10.2.3.Online Pharmacies
10.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11. Middle East and Africa (MEA) Inclusion Body Myositis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Molecule Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.ACE-083
11.1.2.Aceneuramic Acid ER
11.1.3.ALZ-1903
11.1.4.UX-001P
11.1.5.UX-007
11.1.6.Others
11.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hospital Pharmacies
11.2.2.Retail Pharmacies
11.2.3.Online Pharmacies
11.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12. Latin America Inclusion Body Myositis Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Molecule Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.ACE-083
12.1.2.Aceneuramic Acid ER
12.1.3.ALZ-1903
12.1.4.UX-001P
12.1.5.UX-007
12.1.6.Others
12.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hospital Pharmacies
12.2.2.Retail Pharmacies
12.2.3.Online Pharmacies
12.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Acceleron Pharma Inc.
13.2.2.Abcuro, Gradalis, Inc.
13.2.3.KPI Therapeutics Inc.
13.2.4.Milo Biotechnology LLC
13.2.5.Novartis AG
13.2.6.Ultragenyx Pharmaceutical Inc.
13.2.7.Orphazyme ApS
13.2.8.Nobelpharma Co Ltd
13.2.9.New Zealand Pharmaceuticals Ltd.
13.2.10.Gradalis, Inc.
14. Research Methodology 
15. Appendix and Abbreviations 

Key Market Players

  • Acceleron Pharma Inc.
  • Abcuro, Gradalis, Inc.
  • KPI Therapeutics Inc.
  • Milo Biotechnology LLC
  • Novartis AG
  • Ultragenyx Pharmaceutical Inc.
  • Orphazyme ApS
  • Nobelpharma Co Ltd
  • New Zealand Pharmaceuticals Ltd.
  • Gradalis, Inc.

Related Industry Reports